Cargando…
Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis
Hypertriglyceridemia is associated with a number of severe diseases such as acute pancreatitis and coronary artery disease. In severe hypertriglyceridemia (SHTG, triglycerides > 1,000 mg/dL), rapid lowering of plasma triglycerides (TG) has to be achieved. Treatment regimes include nutritional int...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374106/ https://www.ncbi.nlm.nih.gov/pubmed/22528130 http://dx.doi.org/10.1007/s11789-012-0042-x |
_version_ | 1782235596592250880 |
---|---|
author | Ewald, Nils Kloer, Hans-Ulrich |
author_facet | Ewald, Nils Kloer, Hans-Ulrich |
author_sort | Ewald, Nils |
collection | PubMed |
description | Hypertriglyceridemia is associated with a number of severe diseases such as acute pancreatitis and coronary artery disease. In severe hypertriglyceridemia (SHTG, triglycerides > 1,000 mg/dL), rapid lowering of plasma triglycerides (TG) has to be achieved. Treatment regimes include nutritional intervention, the use of antihyperlipidemic drugs, and therapeutic apheresis. Apheretic treatment is indicated in medical emergencies such as hypertriglyceridemic pancreatitis. Reviewing the current literature, plasmapheresis appears to be a safe and useful therapeutic tool in patients suffering from SHTG. Apheretic treatment is able to remove the causative agent for pancreatic inflammation. Data suggests that the use of apheresis should be performed as early as possible in order to achieve best results. The use of plasmapheresis, however, is limited due to the rather high costs and the limited availability of the procedure. |
format | Online Article Text |
id | pubmed-3374106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-33741062012-06-14 Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis Ewald, Nils Kloer, Hans-Ulrich Clin Res Cardiol Suppl Article Hypertriglyceridemia is associated with a number of severe diseases such as acute pancreatitis and coronary artery disease. In severe hypertriglyceridemia (SHTG, triglycerides > 1,000 mg/dL), rapid lowering of plasma triglycerides (TG) has to be achieved. Treatment regimes include nutritional intervention, the use of antihyperlipidemic drugs, and therapeutic apheresis. Apheretic treatment is indicated in medical emergencies such as hypertriglyceridemic pancreatitis. Reviewing the current literature, plasmapheresis appears to be a safe and useful therapeutic tool in patients suffering from SHTG. Apheretic treatment is able to remove the causative agent for pancreatic inflammation. Data suggests that the use of apheresis should be performed as early as possible in order to achieve best results. The use of plasmapheresis, however, is limited due to the rather high costs and the limited availability of the procedure. Springer-Verlag 2012-02-28 2012-06 /pmc/articles/PMC3374106/ /pubmed/22528130 http://dx.doi.org/10.1007/s11789-012-0042-x Text en © The Author(s) 2012 |
spellingShingle | Article Ewald, Nils Kloer, Hans-Ulrich Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis |
title | Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis |
title_full | Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis |
title_fullStr | Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis |
title_full_unstemmed | Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis |
title_short | Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis |
title_sort | treatment options for severe hypertriglyceridemia (shtg): the role of apheresis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374106/ https://www.ncbi.nlm.nih.gov/pubmed/22528130 http://dx.doi.org/10.1007/s11789-012-0042-x |
work_keys_str_mv | AT ewaldnils treatmentoptionsforseverehypertriglyceridemiashtgtheroleofapheresis AT kloerhansulrich treatmentoptionsforseverehypertriglyceridemiashtgtheroleofapheresis |